Issue Date: February 3, 2014
… And Seals Antibiotics Pact With FOB
AstraZeneca and FOB Synthesis, a Kennesaw, Ga.-based custom synthesis and antibiotic development firm, will work together to develop combination therapy antibiotics to address drug-resistant infections. The companies will potentially combine AstraZeneca’s preclinical β-lactamase inhibitor (BLI) with carbapenem antibiotics in preclinical studies at FOB. AstraZeneca will develop combinations of its BLI with FOB’s FSI-1671 and FSI-1686 through Phase I, after which it has an option to license the compounds. Financial terms of the deal were not disclosed.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society